The shift toward allogeneic — or “off-the-shelf” — cell therapies is one of the most significant trends in the cell and gene therapy industry. Unlike autologous therapies that require manufacturing a unique product from each patient’s own cells, allogeneic approaches use donor-derived cells that can be manufactured in advance, banked, and administered to multiple patients. Perinatal tissues — cord blood, placental tissue, umbilical cord tissue, and amniotic membrane — have emerged as particularly valuable sources of starting material for these therapies.[1][2]
What Are Perinatal Tissues?
Perinatal tissues are biological materials associated with birth, including the umbilical cord, placenta, amniotic membrane, and cord blood. These tissues are normally discarded after delivery, making them an abundant, ethically sourced supply of cells with unique biological properties. With informed consent from the mother, these tissues can be collected after birth and processed to isolate specific cell populations for therapeutic use.
The primary perinatal tissue sources used in cell therapy include umbilical cord blood, which is rich in CD34+ hematopoietic stem cells (HSCs), hematopoietic progenitor cells, and naive immune cells including T cells, NK cells, and regulatory T cells.[1][3] Wharton’s jelly — the gelatinous connective tissue within the umbilical cord — contains abundant mesenchymal stromal cells (MSCs).[2] Placental tissue provides both MSCs and decidua stromal cells, and amniotic membrane contains amniotic epithelial cells and MSCs along with beneficial growth factors and cytokines.
Why Perinatal Tissue Is Uniquely Suited for Allogeneic Therapies
The biological properties of perinatal cells make them particularly well-suited for allogeneic applications where donor cells must function in a recipient with a different immune profile.
Immunological Naivety
Cord blood lymphocytes have a predominantly naive phenotype with immature immune cell populations.[3][4] They produce fewer inflammatory cytokines and express less interferon-gamma compared to adult lymphocytes.[4] This immunological immaturity translates to a lower risk of graft-versus-host disease (GvHD) — one of the most serious complications of allogeneic cell therapy — even when HLA matching is imperfect.[1][5]
Reduced HLA Immunogenicity
Umbilical cord blood-derived lymphocytes are associated with comparatively attenuated alloreactivity, consistent with reduced antigen-presentation and co-stimulatory capacity relative to adult hematopoietic sources.[4] This creates what researchers describe as an “immune privileged” status, enabling transplantation with less stringent HLA matching requirements. Published research has demonstrated that cord blood grafts can tolerate HLA mismatches at up to two loci — a significantly wider margin than adult bone marrow, which requires stricter matching for comparable outcomes.[1][5]
Superior Proliferative Capacity
Cord blood and perinatal tissue-derived cells demonstrate higher proliferative capacity and reduced senescence compared to cells derived from adult tissues.[3] This characteristic is particularly valuable in manufacturing contexts where cell expansion is required to produce therapeutic doses from limited quantity of starting material.
Current Clinical Applications
Perinatal-derived cell therapies already have a meaningful clinical track record. Cord blood HSCs remain the most established application, with FDA-cleared products approved for bone marrow failure, hematologic malignancies, congenital immunodeficiency syndromes, hemoglobinopathies, and inherited metabolic diseases.[6]
Beyond established HSC transplantation, the clinical pipeline is expanding rapidly. The number of trials using non-cord blood perinatal sources doubled between 2013 and 2017 — from 28 to 56 trials — with 84% based on MSC therapies from cord blood, cord tissue, and placenta.[2] Emerging applications include CAR-NK cell therapies derived from cord blood, placental decidua stromal cells for GvHD treatment, and Wharton’s jelly MSC programs for orthopedic injury, spinal cord injury, myocardial infarction, and neurological disorders.[2]
A notable recent milestone is the EU conditional marketing authorization of Zemcelpro (dorocubicel), the first and only EU-approved allogeneic cell therapy using expanded cord blood CD34+ cells for hematologic malignancies requiring allogeneic HSC transplant when no suitable donor is available.[7][8]
The Off-the-Shelf Manufacturing Advantage
One of the most compelling aspects of perinatal tissue for allogeneic therapy is the manufacturing model it enables. A single cord blood unit or placental tissue donation can be processed, expanded, and banked to produce many therapeutic doses. This fundamentally changes the economics and logistics of cell therapy compared to the one-patient-one-manufacturing-run model of autologous approaches.[9]
Regulatory Framework for Perinatal Tissue
Perinatal tissues are regulated as Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) under FDA 21 CFR Parts 1270 and 1271, overseen by the Center for Biologics Evaluation and Research (CBER). The regulatory pathway depends on the degree of manipulation and intended use.
Minimally manipulated products used for homologous purposes may qualify as Section 361 HCT/Ps, which do not require premarket FDA approval but must meet donor eligibility and current good tissue practice (cGTP) requirements. Products involving more-than-minimal manipulation — such as culture-expanded MSCs — are regulated as Section 351 biologics requiring an IND, clinical trials, and a Biologics License Application (BLA).
Sourcing Considerations for Therapy Developers
For cell therapy companies evaluating perinatal tissue sources, several factors should guide the selection of a tissue supplier. Ethical sourcing under IRB-approved protocols with proper informed consent is fundamental. Comprehensive donor testing meeting FDA requirements ensures safety and regulatory compliance. HLA genotyping on each product is essential for allogeneic programs that require HLA-matched or HLA-characterized starting material.
For fresh perinatal tissues, supplier proximity and end-to-end control of local collection and processing are critical, as prolonged transport and delays to processing can compromise cell viability, recovery, and functional performance.[10] Selecting a partner that can source and process tissues locally helps minimize ischemic time and handling variability, improving lot-to-lot consistency of the resulting starting material.
Product format flexibility also matters. The ability to obtain fresh, frozen, or cryopreserved materials in both research-grade and GMP-grade formats enables seamless program progression from discovery through clinical development. And supply chain reliability — including direct control over collection, processing, and distribution — reduces the risk of material shortages that can delay clinical timelines.
Looking Ahead
The convergence of clinical validation, manufacturing scalability, regulatory clarity, and growing commercial investment positions perinatal tissue as a cornerstone of the allogeneic cell therapy future.[2][7] As more off-the-shelf therapies advance through clinical development and toward commercialization, the demand for high-quality, well-characterized perinatal starting materials will continue to grow — making the choice of tissue supplier an increasingly strategic decision for therapy developers.
Ready to accelerate your cell therapy program? Contact OrganaBio at organabio.com to speak with our team.
References
[1] Ballen KK, et al. “Improving Engraftment and Immune Reconstitution in Umbilical Cord Blood Transplantation.” Frontiers in Immunology, 2014;5:68. doi:10.3389/fimmu.2014.00068
[2] Verter F, Couto PS, Bersenev A. “A Dozen Years of Clinical Trials Performing Advanced Cell Therapy with Perinatal Cells.” Future Science OA, 2018;4(10):FSO351. doi:10.4155/fsoa-2018-0085
[3] Choudhery MS, et al. “Implications of maternal-fetal health on perinatal stem cell banking.” Stem Cell Research & Therapy, 2024;15(1):67. doi:10.1186/s13287-024-03680-0
[4] Kang J, et al. “Immune Regulatory Cells in Umbilical Cord Blood and Their Potential Roles in Transplantation Tolerance.” Critical Reviews in Oncology/Hematology, 2010;79(2):112–126. doi:10.1016/j.critrevonc.2010.07.009
[5] Park SS, et al. “Recipient-specific tolerance after HLA-mismatched umbilical cord blood stem cell transplantation.” Transplantation, 2005;80(10):1321–1330. doi:10.1097/01.tp.0000188172.26700.2f
[6] FDA. “Approved Cellular and Gene Therapy Products.” U.S. Food and Drug Administration, updated 2025. fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
[7] European Medicines Agency. “New stem cell therapy to treat patients with blood cancers: Zemcelpro (dorocubicel).” EMA, June 2025. ema.europa.eu/en/news/new-stem-cell-therapy-treat-patients-blood-cancers
[8] ExCellThera Inc. “Zemcelpro (UM171 Cell Therapy) receives EC authorization as the first and only cell therapy for blood cancer patients without access to suitable donor cells.” Press Release, August 27, 2025.
[9] Cohen S, Roy J, Lachance S, et al. “Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1–2 safety and feasibility study.” Lancet Haematology, 2020;7(2):e134–e145. doi:10.1016/S2352-3026(19)30202-9
[10] Cell & Gene Therapy Insights. “The Importance of Collection, Processing & Biopreservation Best Practices in Determining CAR-T Starting Material Quality.” Cell & Gene Therapy Insights, 2018.
